A Strategic Implementation Framework for Integrating Pharmacogenomics (PGx) into Personalized Healthcare in Saudi Arabia.

Implementation framework based on gene-drug priority tiers (clinical impact, population relevance, feasibility) and a six-phase roadmap.

The authors propose an implementation framework for pharmacogenomics in Saudi Arabia, based on a structured policy analysis and evidence synthesis of Saudi, regional and international data, on a comparison of implementation capabilities across established models, and on a descriptive assessment of national readiness across the main health system domains. The country's strengths are genomic evidence and digital health infrastructure, but large gaps exist in governance, laboratory standardisation, electronic health record interoperability, clinical decision support, workforce readiness, reimbursement and outcome evaluation. Using published evidence and structured expert judgement, they propose gene-drug priority tiers according to clinical impact, population relevance and feasibility, and five pathways for initial implementation: CYP2C19-clopidogrel, DPYD-fluoropyrimidines, TPMT/NUDT15-thiopurines, HLA-guided anticonvulsant prescribing and HLA-B*57:01-abacavir. The framework could be supported by the Population Health Observatory and a six-phase roadmap, moving from governance and technical design to multicentre pilots, national scale-up and continuous evaluation.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

This text belongs to health policy rather than demonstration: the ranking of gene-drug pairs rests on a structured analysis and expert judgement whose search strategy and number of sources the abstract does not describe, national readiness is assessed only descriptively, and no patient outcome data are presented. The most solid lesson is the authors' own finding: the gaps identified (governance, record interoperability, decision support, reimbursement, outcome evaluation) are organisational, while genomic evidence and digital infrastructure are already in place, which shifts the challenge from analysis to integration into the care pathway. For a reader outside the Saudi context, the document is worth more as a checklist than as a transferable model, and the abstract does not say whether the priority tiers would survive a different ranking method.

Analysis by Dr Thibaut Benquey